
|Videos|March 28, 2017
Alternative Sunitinib Scheduling for mRCC
Author(s)Eric Jonasch, MD
Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the phase II study of alternative sunitinib (Sutent) scheduling in patients with metastatic renal cell carcinoma (mRCC).
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5


































